DexCom, Inc. (DXCM) CEO Kevin R. Sayer Sells 12,000 Shares

DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 12,000 shares of the stock in a transaction on Monday, November 20th. The stock was sold at an average price of $55.00, for a total transaction of $660,000.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Kevin R. Sayer also recently made the following trade(s):

  • On Wednesday, September 20th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The shares were sold at an average price of $69.34, for a total transaction of $416,040.00.

DexCom, Inc. (NASDAQ DXCM) traded up $1.14 during midday trading on Thursday, reaching $59.97. 970,194 shares of the company were exchanged, compared to its average volume of 1,454,162. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC increased its holdings in DexCom by 9.9% during the second quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after buying an additional 978,898 shares during the last quarter. Janus Henderson Group PLC increased its holdings in DexCom by 29.2% during the third quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after buying an additional 1,991,094 shares during the last quarter. Vanguard Group Inc. increased its holdings in DexCom by 3.4% during the second quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after buying an additional 224,808 shares during the last quarter. BlackRock Inc. increased its holdings in DexCom by 5.5% during the second quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after buying an additional 230,542 shares during the last quarter. Finally, Brown Advisory Inc. increased its holdings in DexCom by 57.2% during the third quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after buying an additional 1,515,134 shares during the last quarter.

A number of research analysts have weighed in on DXCM shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Tuesday, August 22nd. BMO Capital Markets reaffirmed a “buy” rating and issued a $90.00 price objective on shares of DexCom in a research note on Friday, September 8th. Jefferies Group reaffirmed a “buy” rating and issued a $91.00 price objective on shares of DexCom in a research note on Thursday, September 28th. Stephens reaffirmed a “buy” rating and issued a $70.00 price objective (down from $83.00) on shares of DexCom in a research note on Thursday, September 28th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $87.00 price objective on shares of DexCom in a research note on Thursday, September 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $70.69.

COPYRIGHT VIOLATION NOTICE: “DexCom, Inc. (DXCM) CEO Kevin R. Sayer Sells 12,000 Shares” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.thelincolnianonline.com/2017/12/08/dexcom-inc-dxcm-ceo-kevin-r-sayer-sells-12000-shares-updated-updated.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply